Luis Peña, Evommune CEO
October 31, 2024 08:00 AM EDT
Financing
Startups

Evom­mune rais­es $115M for I&I pipeline and pre­pares for Phase 2 re­sults

Kyle LaHucik

Senior Reporter

An­oth­er in­flam­ma­tion and im­munol­o­gy start­up has at­tract­ed big bucks.

On Thurs­day, Evom­mune an­nounced a $115 mil­lion raise to back a pipeline an­tic­i­pat­ed to have mul­ti­ple …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times